Synthesis, in vitro activity and in vivo toxicity of the new 2,3-dinitrobutadiene derivative (1E,3E)-1,4-bis(2-naphthyl)-2,3-dinitro-1,3-butadiene

Pharmacological Research

Volumn 56, Issue 4, 2007, Pages 318-328

  Viale, Maurizio ^a   Petrillo, Giovanni ^b   Aiello, Cinzia ^a   Fenoglio, Carla ^c   Cordazzo, Cinzia ^a   Mariggiò, Maria A ^d   Cassano, Amalia ^d   Prevosto, Claudia ^a   Ognio, Emanuela ^a   Maccagno, Massimo ^b   Bianchi, Lara ^b   Vaccarone, Rita ^c   Rizzato, Egon ^e   Spinelli, Domenico ^e  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiproliferative activity; Apoptosis; Naphthylnitrobutadienes; Toxicity

Indexed keywords

1,4 BIS(1 NAPHTHYL) 2,3 DINITRO 1,3 BUTADIENE; ALKENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMICAL STRUCTURE; DNA CROSS LINKING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; ISOMER; LETHAL DOSE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BUTADIENES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CROSS-LINKING REAGENTS; DNA; FEMALE; HUMANS; KIDNEY; LIVER; MICE; NAPHTHALENES; SPLEEN; STEREOISOMERISM; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 34848815629     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.07.009     Document Type: Article

References (34)

1. Ferlay J., Bray F., Pisani P., and Parkin D.M. Globocan 2000: cancer incidence, mortality and prevalence worldwide, version 1.0 (IARC, CancerBase No 5) (2001), IARC Press, Lyon
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
3. Kamangar F., Dores G.M., and Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 (2006) 2137-2150
4. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334 (1996) 1150-1155
5. Luqmani Y.A. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14 Suppl. 1 (2005) 35-48
6. Donnenberg V.S., and Donnenberg A.D. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45 (2005) 872-877
7. Longley D.B., and Johnston P.G. Molecular mechanisms of drug resistance. J Pathol 205 (2005) 275-292
8. Schwartsmann G., Ratain M.J., Cragg G.M., Wong J.E., Saijo N., Parkinson D.R., et al. Anticancer drug discovery and development throughout the world. J Clin Oncol 20 Suppl. 15 (2002) 47S-59S
9. Neidle S., and Thurston D.E. Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 5 (2005) 285-296
10. Viale M., Ottone M., Chiavarina B., Mariggiò M.A., Prevosto C., Dell'Erba C., et al. Preliminary evaluation in vitro of the inhibition of cell proliferation, cytotoxicity and induction of apoptosis by 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene. Invest New Drug 22 (2004) 359-367
11. Novi M., Ottone M., Dell'Erba C., Barbieri F., Chiavarina B., Maccagno M., et al. 1,4-Bis(1-naphthyl)-2,3-dinitro-1,3-butadiene a novel anticancer compound effective against tumour cell lines characterized by different mechanisms of resistance. Oncol Rep 12 (2004) 91-96
12. Dell'Erba C., Chiavarina B., Fenoglio C., Petrillo G., Cordazzo C., Boncompagni E., et al. Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene in gastrointestinal tumour cell lines and preliminary evaluation of its toxicity in vivo. Pharmacol Res 52 (2005) 271-282
13. Petrillo G, Fenoglio C, Ognio E, Aiello C, Spinelli D, Mariggiò MA, Maccagno M, Morganti S, Cordazzo C, Viale M. Naphthylnitrobutadienes as pharmacologically-active molecules: evaluation of the in vivo antitumour activity. Invest New Drug 2007; doi:10.1007/s10637-007-9065-4.
14. Dell'Erba C., Mele A., Novi M., Petrillo G., and Stagnaro P. Synthetic exploitation of the ring-opening of 3,4-dinitrothiophene. A novel access to 1,4-dialkyl- and 1,4-diaryl-2,3-dinitro-1,3-butadienes. Tetrahedron Lett 31 (1990) 4933-4936
15. Dell'Erba C., Mele A., Novi M., Petrillo G., and Stagnaro P. Synthetic exploitation of the ring-opening of 3,4-dinitrothiophene. Access to 1,4-disubstituted 2,3-dinitro-1,3-butadienes and 2,3-butanedione dioximes. Tetrahedron 48 (1992) 4407-4418
16. Bianchi L., Dell'Erba C., Maccagno M., Morganti S., Petrillo G., Rizzato E., et al. Nitrobutadienes from β-nitrothiophenes: valuable building-blocks in the overall ring-opening/ring-closure protocol to homo- or hetero-cycles. Arkivoc vii (2006) 169-185
17. Bianchi L., Maccagno M., Petrillo G., Sancassan F., Spinelli D., and Tavani C. 2,3-Dinitro-1,3-butadienes: versatile building-blocks from the ring-opening of 3,4-dinitrothiophene. In: Attanasi O.A., and Spinelli D. (Eds). Targets in heterocyclic systems: chemistry and Properties vol 10 (2006), Società Chimica Italiana, Rome 1-23
18. Louie K.G., Behrens B.C., Kinsella T.J., Hamilton T.C., Grotzinger K.R., McKoy W.M., et al. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 45 (1985) 2110-2115
19. Lieber M., Smith B., Szakal A., Nelson-Rees W., and Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 17 (1976) 62-70
20. Chen J.Y., Funk W.D., Wright W.E., Shay J.W., and Minna J.D. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8 (1993) 2159-2166
21. Akagi T., and Kimoto T. Human cell line (HGC-27) derived from the metastatic lymph node of gastric cancer. Acta Med Okayama 30 (1976) 215-219
22. Tompkins W.A., Watrach A.M., Schmale J.D., Schultz R.M., and Harris J.A. Cultural and antigenic properties of newly established cell strains derived from adenocarcinomas of the human colon and rectum. J Natl Cancer Inst 52 (1974) 1101-1110
23. Weiss A., Wiskocil R.L., and Stobo J.D. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol 133 (1984) 123-128
24. Cailleau R., Young R., Olive M., and Reeves Jr. W.J. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53 (1974) 661-674
25. Zeuthen J., Norgaard J.O., Avner P., Fellous M., Wartiovaara J., Vaheri A., et al. Characterization of a human ovarian teratocarcinoma-derived cell line. Int J Cancer 25 (1980) 19-23
26. Evans V.J., Larock J.F., Yosida T.H., and Potter M. A new tissue culture isolation and explantation of the P388 lymphocytic neoplasm in a chemically characterized medium. Exp Cell Res 32 (1963) 212-217
27. Hussain R.F., Nouri A.M.E., and Oliver R.T.D. A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 160 (1993) 89-96
28. Coluccia M., Boccarelli A., Mariggiò M.A., Cardellicchio N., Caputo P., Intini F.P., et al. Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent. Chem-Biol Interact 98 (1995) 251-266
29. Geske F.J., and Gerschenson L.E. The biology of apoptosis. Hum Pathol 32 (2001) 1029-1038
30. Fulda S., and Debatin K.M. Modulation of apoptosis signaling for cancer therapy. Immunol Ther Exp (Warsz) 54 (2006) 173-175
31. Green A.M., and Steinmetz N.D. Monitoring apoptosis in real time. Cancer J 8 (2002) 82-92
32. Gadducci A., Cosio S., Muraca S., and Genazzani A.R. Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. Eur J Gynaecol Oncol 23 (2002) 390-396
33. Gonzales V.M., Fuertes M.A., Alonso C., and Perez J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol Pharmacol 59 (2001) 657-663
34. Schmidt S., Rainer J., Ploner C., Presul E., Riml S., and Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 11 Suppl. 1 (2004) S45-S55